Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132820 · ClinicalTrials.gov registry record · Phase 2
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT01132820: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01132820 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01132820, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate may stop the growth of tumor cells by blocking proteins made by tumors that can stimulate growth of tumor cells as well as blood vessels in and around tumors.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cediranib Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-06 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132820
The ClinicalTrials.gov registry entry for NCT01132820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01132820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01132820 about?
NCT01132820 is a clinical study titled "Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer". This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate may stop the growth of t...
What is the current status of trial NCT01132820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2010-06. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01132820?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT01132820?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.